AEterna Zentaris Inc. (AEZS)

Market Cap	18.93M
Revenue (ttm)	6.63M
Net Income (ttm)	-13.46M
Shares Out	4.86M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,789
Open	3.75
Previous Close	3.87
Day's Range	3.75 - 4
52-Week Range	3.51 - 11.5
Beta	1.64
Analysts	Buy
Price Target	n/a
Earnings Date	Nov 3, 2022

About AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license ag...

• Industry: Biotechnology
• IPO Date: Jul 18, 1996
• CEO: Klaus Paulini
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: AEZS

Financial Performance

In 2021, AEZS's revenue was $5.26 million, an increase of 44.03% compared to the previous year's $3.65 million. Losses were -$8.37 million, 63.5% more than in 2020.

Analyst Forecast

No stock price forecast available yet.

Price Target

n/a

Analyst Consensus: Buy